Biocon Limited reported a 10% year-on-year growth in operating revenue for Q1 FY27, reaching INR 2,855 crores, driven by a strong 16% increase in its biosimilars segment. The company’s net profit saw a significant 245% surge to INR 145 crores. The transcript highlights strategic focus on profitable growth, expansion in key geographies, and continued R&D investments.
Biocon Reports Strong Q1 FY27 Performance
Biocon Limited announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), showcasing robust growth and strategic progress. The company achieved a consolidated operating revenue of 10% year-on-year growth, highlighting a steady increase in its top line. This performance underscores the company’s strategic positioning and operational efficiencies.
Segmental Highlights and Growth Drivers
The biosimilars business emerged as a key growth engine, reporting a significant 16% year-on-year revenue increase. This growth was primarily propelled by the North American market. The generics business also demonstrated strength, with revenues up by 21% year-on-year, supported by recent product launches and improved operating leverage. However, the services segment experienced a decline of 16% year-on-year due to specific client-related impacts.
Profitability and Financial Outlook
EBITDA for the quarter stood at INR 902 crores with a margin of 21%. The company reported a substantial 245% year-on-year increase in reported net profit to INR 145 crores before exceptional items. Biocon emphasized its commitment to profitable growth, focusing on stronger earnings, improved free cash flow generation, and enhanced shareholder value.
Geographical Expansion and Future Strategy
Biocon detailed its strategic initiatives across key geographies. In North America, the company continues to strengthen its position with the commercialization of key biosimilar products. In Europe, Biocon offers a combined portfolio of 11 biosimilars and 8 generic medicines, expanding its market presence through strategic partnerships. Emerging markets remain a significant growth opportunity, with new product launches and regulatory approvals gaining momentum.
Key Product Updates and R&D
The transcript highlighted the launch of the denosumab biosimilar and bevacizumab biosimilar in European markets. Furthermore, a significant milestone was achieved with the EMA approval for a second drug product line at the Malaysia insulin facility, expected to boost global insulin franchise growth. R&D investments for the biosimilars segment stood at 7% of revenues.
Management Commentary
Kiran Mazumdar-Shaw, Executive Chairperson, expressed confidence in Biocon’s strategic and financial strength. The management reiterated the focus on translating capabilities into accelerated growth, improved profitability, and stronger cash generation. The company is closely monitoring market dynamics and competitive landscapes to ensure sustainable and profitable expansion.
Source: BSE
